Genome-wide bioinformatics analysis reveals CTCFL is upregulated in high-grade epithelial ovarian cancer

MI GONG1,2*, CHANGSHENG YAN3*, YI JIANG1*, HUANGYANG MENG1, MINGMING FENG1 and WENJUN CHENG1

1Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029; 2Department of Gynecology, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu 223300; 3Department of Gastroenterology, Zhongshan Hospital Affiliated to Xiamen University, Xiamen, Fujian 361004, P.R. China

Received October 20, 2018; Accepted June 12, 2019

DOI: 10.3892/ol.2019.10736

Correspondence to: Professor Wenjun Cheng, Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, 368 North Jiangdong Road, Nanjing, Jiangsu 210029, P.R. China
E-mail: chengwenjundoc@163.com

*Contributed equally

Key words: epithelial ovarian cancer, grade, gene expression, bioinformatics, CCCTC-binding factor like

Abstract. Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy that threatens the health of females. Previous studies have demonstrated that the survival outcomes of patients with different EOC grades varied. Therefore, the EOC grade is considered to serve as a distinctive prognostic factor. To date, the evaluation of ovarian cancer grade relies on pathological examination and a quantitative index for diagnosis is lacking. Furthermore, the dysregulation of genes has been demonstrated to exert pivotal functions in the carcinogenesis of EOCs. Therefore, the identification of effective biomarkers associated with EOC grade is of importance for the development of therapeutic regimens, and also contributes to the prediction of EOC prognosis.

Gene microarrays have been increasingly applied for the identification of potential molecular biomarkers for numerous diseases including EOC. In the present study, four public microarray datasets (GSE26193, GSE63885, GSE30161 and GSE9891) were analyzed. A total of 6,103 upregulated probes corresponding to 5,766 genes, and 4,004 downregulated probes corresponding to 3,707 genes were identified in the GSE26193, GSE63885 and GSE30161 datasets. ALK and LTK ligand 2 was the most downregulated gene associated with the tumor grade, while CCCTC-binding factor like (CTCFL), EGF like domain multiple 6, radical S-adenosyl methionine domain containing 2 and SAM and HD domain containing deoxynucleoside triphosphate triphosphohydrolase 1 were the most upregulated genes associated with EOC grade. The GSE9891 dataset was added for further analysis. Only one probe (1552368_at) encoding for CTCFL was identified to be consistently upregulated in the four examined datasets. Immunohistochemical analysis was used to detect the expression of CTCFL between low- and high-grade EOC tissues and revealed that the EOC grade was closely associated with CTCFL level. This was corroborated via the reverse transcription-quantitative polymerase chain reaction. Taken together, the results of the present study suggested that CTCFL is upregulated in high-grade epithelial ovarian cancer.

Introduction

Epithelial ovarian cancer (EOC) has the highest mortality rate among gynecological malignancies, and remains the most lethal type that threatens the life and health of females (1,2). The majority of patients with EOCs are diagnosed at an advanced stage of the disease (3-6), and numerous studies have demonstrated that the outcome of patients with EOC depends on the tumor grade (7). Following surgery and platinum-based combination chemotherapy, the recurrence rate of low-grade EOCs (LG-EOCs) was lower and the survival rate was higher compared with high-grade EOCs (HG-EOCs) (8). Therefore, the EOC grade is considered to serve as a distinctive risk factor. At present, the assessment of grade in EOC samples is based on a dualistic classification system proposed by Shih Ie and Kurman in 2004 (9). EOC is divided into types I and II; type I (low-grade) EOC presents with a good prognosis; however, it is unresponsive to chemotherapy. Type II (high-grade) EOC has a poor prognosis, yet it is sensitive to chemotherapy (9). The evaluation of ovarian cancer grade currently relies solely on clinicopathological parameters: a molecular standard for diagnosis is yet to be established (10). Therefore, identifying effective biomarkers associated with the EOC grade is of clinical significance for developing effective therapeutic strategies for patients with EOC, and may contribute to the prediction of prognosis.

Gene microarrays are valued for their strong application prospects, as they can monitor expression levels of thousands of genes simultaneously. At present, due to the publication of gene microarray information, an increasing
number of researchers are devoted to exploring unknown mechanisms with this methodology. However, limited sample sizes, different microarray platforms and different statistical methods are limitations of this approach (11). Bioinformatics analysis may be conducted to overcome these drawbacks.

In the past decades, several studies investigated dysregulated genes and their potential functions in EOC (12,13). However, to the best of our knowledge, few studies investigating molecular biomarkers associated with EOCs grade have been reported. Therefore, there is a requirement for the identification of reliable biomarkers to distinguish between LG-EOCs and HG-EOCs. The present study used bioinformatics methods to investigate and identify differentially expressed genes in different EOC grades.

Materials and methods

Microarray datasets filtering. To analyze the differentially expressed genes between HG-EOCs and LG-EOCs, EOC datasets were downloaded from the Gene Expression Omnibus (GEO; https://www.ncbi.nlm.nih.gov/geo/) database, using the keywords ‘ovarian cancer’ and ‘GPL570’. Subsequently, four public microarray datasets, including GSE26193 (14), GSE63885 (15), GSE30161 (16) and GSE9891 (17), were selected based on the following criteria (11): i) Expression profiling by array; ii) availability of raw CEL files; iv) GPL570 platforms; and v) EOC samples associated with EOC grades. As a result, the GSE26193, GSE63885, GSE30161 and GSE9891 datasets, consisting of 107, 80, 54 and 280 EOC samples associated with EOC grades, respectively, were included in the present study. The GSE26193 dataset consisted of 40 LG-EOCs and 67 HG-EOCs samples, GSE63885 contained 10 LG-EOCs and 70 HG-EOCs samples, GSE30161 included 21 LG-EOCs and 33 HG-EOCs samples, and GSE9891 was composed of 119 LG-EOCs and 161 HG-EOCs samples.

Data analysis. The publicly available raw CEL files downloaded from the GEO database pre-treated by robust multichip average (RMA) analysis in the affy package (version 3.9; http://www.bioconductor.org/packages/release/bioc/html/affy.html). In order to analyze dysregulated genes in each dataset, the limma package (version 3.9; http://bioconductor.org/packages/release/bioc/html/limma.html) was used. The unregulated or downregulated probes, where P<0.05 and log2 fold change (FC)>1 (upregulated genes) or <-1(downregulated genes), were listed. Venn diagrams (bioinfogp.cnb.csic.es/tools/venny.html) were used to analyze the consistently differentially expressed genes in the datasets in the present study. To further expand the sample size, the InSilicoMerging (12) approach was used to merge the normalized datasets selected for inclusion in the current study and the ‘RankProd’ (19) approach was applied to identify the dysregulated genes in the merged datasets.

Gene enrichment analysis of dysregulated genes. Gene Ontology analysis for the list of differentially expressed genes identified by RankProd was performed to identify their prevalence in biological processes and in molecular functions and pathways, using the Database for Annotation, Visualization and Integrated Discovery (DAVID Bioinformatics Resources; version 6.8; https://david.ncifcrf.gov) (20). The ggplot2 package (21) was used to visualize the main functional pathways of dysregulated genes.

Tissue sample collection. A total of 82 EOC tissue samples (including 36 LG-EOCs and 46 HG-EOCs) were collected from patients with an age range of 35-73 years who had received surgery at The First Affiliated Hospital of Nanjing Medical University (Nanjing, China) between July 2011 to December 2018. The resected tissues were assessed by histological analysis. The patients enrolled had been histopathologically diagnosed with primary ovarian cancer, and had not received any other treatment prior to surgical resection. The tissue samples were immediately stored at -80°C until subsequent analysis. Patients were followed up every 3 months after surgery, during which no patients were lost to follow-up. The follow-up information was recorded comprehensively. Written informed consent for the collection and analysis of tissue specimens in the present study was obtained from every patient; the study was approved by the Research Ethics Committee of Nanjing Medical University. The clinical and pathological characteristics of the patients with EOC are presented in Table I.

RNA isolation and reverse-transcription polymerase chain reaction (RT-qPCR). Total RNA in the EOC tissues was extracted by TRizol® reagent (Invitrogen, CA, USA) according to the manufacturer's protocol. The cDNA reactions prepared using the reverse transcriptase kit (Takara Bio, Inc.) according to the manufacturer's protocol. The mRNA expression of CCCTC-binding factor like (CTCFL) was detected using a standard SYBR Green permix Ex Taq kit (Takara Bio, Inc.) on the 7900 HT real-time instrument (Applied Biosystems; Thermo Fisher Scientific, Inc.). The amplification of CTCFL was performed with an initial step at 94°C for 30 sec, followed by 40 cycles of denaturation at 95°C for 5 sec, annealing at 60°C for 30 sec, and extension at 95°C for 15 sec. The sequences of the primers used were as follows: CTCFL forward, 5'-GTA CTC GCC GAG GAT GGG -3' and reverse, 5'- TCACC GCT AACT TCT GCT TT CA -3'; and GAPDH forward, 5'- CCC ACT CCT CC AC TCT TT GC -3' and reverse, 5'- GGAT CTGC TCT CTC GGA AGAT GAT G -3'. CTCFL mRNA levels were quantified using the 2ΔΔCt method and normalized to GAPDH (22).

Immunohistochemical analysis. Immunohistochemical analysis was performed to detect CTCFL protein expression in the tissue specimens. Analysis revealed that CTCFL was the most upregulated gene in the four datasets and was subsequently selected for immunohistochemical analysis. Briefly, paraffin-embedded tissue blocks were cut into 4-µm thick sections and then placed in a constant temperature box at 65°C for 30 min to deparaffinize. The sections were submerged in the ethylendiaminetetraacetic acid buffer and microwaved for 8 min for antigenic retrieval. 3% hydrogen peroxide in methanol was used to quench the endogenous peroxidase activity. Then 1% goat serum albumin (Abcam) was incubated at room temperature for 5 min to block nonspecific binding.
The sections were subsequently stained with an anti-BORIS (CTCFL) primary antibody (1:200; cat. no. ab187163; Abcam) and incubated overnight at 4°C, and horseradish peroxidase-conjugated goat anti-rabbit IgG secondary antibody (1:1,000; cat. no. ab6721; Abcam) were then incubated at room temperature for 1 h. Finally, images were captured using a high-capacity digital slide scanner (Pannoramic SCAN, 3DHISTECH) at x200 magnification. The sections were evaluated independently by two experienced pathologists. A total of 12 patients with paired serous ovarian cancer patients, were selected from patients enrolled in our study to conduct this experiment.

### Results

**Dysregulated genes between high-and low-grade EOC.** The present study initially analyzed the differentially expressed genes between HG-EOCs and LG-EOCs in each dataset with the limma software package. The three datasets (GSE26193, GSE63885 and GSE30161) were then employed to analyze the consistently differential expressed genes (Fig. 1A). As illustrated in Fig. 1B, there were 90, 733 and 1,489 upregulated genes in the GSE26193, GSE30161 and GSE63885 datasets, respectively. CTCFL (fold change/FC=2.676; percentage of false prediction/pfp<0.01), EGFL6 (FC=2.140; pfp<0.01), radical S-adenosyl methionine domain containing 2 (FC=1.776; pfp<0.01) and SAM and HD domain containing deoxy-nucleoside triphosphate triphosphohydrolase 1 (SAMHD1; FC=1.639; pfp<0.01) were consistently upregulated among these three datasets. Furthermore, 415, 79 and 41 genes were identified as downregulated in the GSE26193, GSE30161 and GSE63885 datasets, respectively. CTCFL (fold change/FC=0.504; pfp<0.01) and ALK and LTK ligand 2 were consistently upregulated among these three datasets. In order to decrease the number of differentially expressed genes, and therefore identify more reliable potential molecular markers for EOC grade, the present study superadded an additional dataset (GSE9891).

**Statistical analysis.** SPSS software (version 18.0; SPSS, Inc., Chicago, IL, USA) and GraphPad Prism software (version 5; GraphPad Software, Inc., La Jolla, CA, USA) were used for all statistical analysis. Data are presented as the mean ± standard error of mean (SEM). The differences between groups were analyzed by the Student’s t-test. For the analysis on the clinicopathological parameters, χ² test and Fisher exact probability method were applied. And Kaplan-Meier analysis and the log-rank test were used for survival analysis. P<0.05 was considered to indicate a statistically significant difference. All experiments were repeated in triplicate.

### Table I. Association between CTCFL expression and clinical pathological characteristics of patients with epithelial ovarian cancer (n=82).

| Clinicopathological feature | Number of cases | CTCFL expression |   |
|-----------------------------|-----------------|------------------|---|
|                            |                 | Low (n=41)       | High (n=41) | P-value |
| Age (years)                |                 |                  |              |         |
| <50                         | 37              | 16               | 21           | 0.2672  |
| ≥50                         | 45              | 25               | 20           |         |
| Histological subtype       |                 |                  |              | 0.1052  |
| Serous                     | 71              | 33               | 38           |         |
| Others                     | 11              | 8                | 3            |         |
| Tumor size (cm)            |                 |                  |              | 0.0344  |
| <8                         | 27              | 18               | 9            |         |
| ≥8                         | 55              | 23               | 32           |         |
| FIGO stage                 |                 |                  |              | 0.0343  |
| I-II                       | 13              | 10               | 3            |         |
| III-IV                     | 69              | 31               | 38           |         |
| Histological grade         |                 |                  |              | 0.0004  |
| Low-grade                  | 36              | 26               | 10           |         |
| High-grade                 | 46              | 15               | 31           |         |
| Lymph node metastasis      |                 |                  |              | 0.3769  |
| Absent                     | 40              | 18               | 22           |         |
| Present                    | 42              | 23               | 19           |         |
| Ascites                    |                 |                  |              | 0.1109  |
| Absent                     | 31              | 12               | 19           |         |
| Present                    | 51              | 29               | 22           |         |

CTCFL, CCCTC-binding factor like; FIGO, International Federation of Gynecology and Obstetrics. *P<0.05.*
As presented in Fig. 2, only one overlapping candidate probe, CTCFL, was identified to be upregulated in the four datasets and no probes were consistently downregulated in the four examined datasets.

**Genome-wide analysis of differential gene expression in merged datasets.** To further enlarge the sample size, the present study initially merged the three datasets by using the InSilicoMerging method. The ‘RankProd’ approach was subsequently used to analyze the differentially expressed genes in the merged datasets. As a result, a total of 6,103 upregulated probes corresponding with 5,766 genes (FC>1; pfp<0.01), and 4,004 downregulated probes corresponding with 3,707 genes (FC<1; pfp<0.01) were identified from the GSE26193, GSE63885 and GSE30161 datasets. The top 20 upregulated and downregulated genes are presented in Tables II and III, respectively.

Consistent with the intersection results among the aforementioned four datasets, CTCFL was the most upregulated gene in HG-EOCs from the merged GSE26193, GSE63885 and GSE30161 datasets (Table I). Therefore, CTCFL may serve as a potent biomarker and CTCFL was subsequently selected as a candidate gene for distinguishing HG-EOCs from LG-EOCs.

**Gene enrichment analysis of dysregulated genes.** To effectively analyze the function of the dysregulated genes in the merged datasets, DAVID was utilized to process the functional enrichment analysis. The biological process (BP) terms associated with the top 3,000 dysregulated genes were...
downloaded. There were 370 significant BP terms associated with the genes upregulated in HG-EOCs and 380 significant BP terms associated with the genes that were downregulated in HG-EOCs. The upregulated genes were enriched in the
Table III. The top 20 most significantly downregulated probes identified from merged three datasets by RankProd in high grade-EOCs.

| Probe ID       | Gene symbol | Fold change (class 1/class 2) | Pfp   | P-value |
|----------------|-------------|-------------------------------|-------|---------|
| 1552368_at     | ZDHHC11B    | 0.842815                      | <0.001| <0.001  |
| 211430_s_at    | MIR8071-2   | 2.242152                      | <0.001| <0.001  |
| 211430_s_at    | MIR8071-1   | 2.242152                      | <0.001| <0.001  |
| 211430_s_at    | IGHV4-31    | 2.242152                      | <0.001| <0.001  |
| 211430_s_at    | IGHM        | 2.242152                      | <0.001| <0.001  |
| 211430_s_at    | IGHG3       | 2.242152                      | <0.001| <0.001  |
| 211430_s_at    | IGHG2       | 2.242152                      | <0.001| <0.001  |
| 211430_s_at    | IGHG1       | 2.242152                      | <0.001| <0.001  |
| 214677_x_at    | IGLJ3       | 2.159827                      | <0.001| <0.001  |
| 214677_x_at    | IGLC1       | 2.159827                      | <0.001| <0.001  |
| 210809_s_at    | POSTN       | 2.145002                      | <0.001| <0.001  |
| 219454_at      | EGFL6       | 2.139953                      | <0.001| <0.001  |
| 204553_at      | CXCL10      | 2.119093                      | <0.001| <0.001  |
| 210096_at      | CYP4B1      | 2.111486                      | <0.001| <0.001  |
| 219768_at      | VTCN1       | 2.05719                       | <0.001| <0.001  |
| 202575_at      | CRABP2      | 2.042067                      | <0.001| <0.001  |
| 209138_x_at    | IGLC1       | 1.982947                      | <0.001| <0.001  |
| 206067_s_at    | WT1         | 1.968892                      | <0.001| <0.001  |
| 230720_at      | RNF182      | 1.965409                      | <0.001| <0.001  |
| 224795_x_at    | IGKC        | 1.958864                      | <0.001| <0.001  |

Class 1 represents high-grade EOCs and class 2 represents low-grade EOCs. EOC, epithelial ovarian cancer; pfp, percentage of false prediction.

Table II. Top 20 most significantly upregulated probes identified from merged three datasets by RankProd in high grade‑EOCs.

| PROBEID       | SYMBOL   | Fold change (class 1/class 2) | Pfp   | P-value |
|---------------|----------|-------------------------------|-------|---------|
| 1552368_at    | CTCFL    | 2.675943                      | <0.001| <0.001  |
| 211430_s_at   | MIR8071-2| 2.242152                      | <0.001| <0.001  |
| 211430_s_at   | MIR8071-1| 2.242152                      | <0.001| <0.001  |
| 211430_s_at   | IGHV4-31 | 2.242152                      | <0.001| <0.001  |
| 211430_s_at   | IGHM      | 2.242152                      | <0.001| <0.001  |
| 211430_s_at   | IGHG3     | 2.242152                      | <0.001| <0.001  |
| 211430_s_at   | IGHG2     | 2.242152                      | <0.001| <0.001  |
| 211430_s_at   | IGHG1     | 2.242152                      | <0.001| <0.001  |
| 214677_x_at   | IGLJ3     | 2.159827                      | <0.001| <0.001  |
| 214677_x_at   | IGLC1     | 2.159827                      | <0.001| <0.001  |
| 210809_s_at   | POSTN     | 2.145002                      | <0.001| <0.001  |
| 219454_at     | EGFL6     | 2.139953                      | <0.001| <0.001  |
| 204553_at     | CXCL10    | 2.119093                      | <0.001| <0.001  |
| 210096_at     | CYP4B1    | 2.111486                      | <0.001| <0.001  |
| 219768_at     | VTCN1     | 2.05719                       | <0.001| <0.001  |
| 202575_at     | CRABP2    | 2.042067                      | <0.001| <0.001  |
| 209138_x_at   | IGLC1     | 1.982947                      | <0.001| <0.001  |
| 206067_s_at   | WT1       | 1.968892                      | <0.001| <0.001  |
| 230720_at     | RNF182    | 1.965409                      | <0.001| <0.001  |
| 224795_x_at   | IGKC      | 1.958864                      | <0.001| <0.001  |

Class 1 represents high-grade EOCs and class 2 represents low-grade EOCs. EOC, epithelial ovarian cancer; pfp, percentage of false prediction.
positive regulation of transcription from RNA polymerase II’,
whilst the downregulated genes were enriched in ‘signal trans-
duction’ and ‘positive regulation of transcription from RNA
polymerase II promoter’. The top 20 BP terms are presented
in Fig. 4A and B.

mRNA expression of CTCFL between HG-EOCs and
LG-EOCs. In order to verify the differential expression of
CTCFL in LG-EOCs and HG-EOCs, RT-qPCR was performed
in 36 LG-EOCs and 46 HG-EOCs tissue samples. As
illustrated in Fig. 5A, the mRNA level of CTCFL was signifi-
cantly upregulated in HG-EOCs compared with LG-EOCs
(P=0.0007). This results indicated that upregulated CTCFL
may be implicated in HG-EOCs. In addition, the present
study divided the 82 patients with EOC into two groups on
the basis of CTCFL expression in tumor tissues (Fig. 5B;
cut-off, 0.1152275). By using the log-rank test, patients with
high expression levels of CTCFL were observed to have a poor
outcome compared with patients with low expression levels
of CTCFL (P=0.0084, Fig. 5C). Notably, the association between
clinical pathological characteristics and CTCFL expression
revealed that high expression levels of CTCFL were signifi-
cantly associated with tumor size (P=0.0344), the International
Federation of Gynecology and Obstetrics stage (P=0.0343)
and histological grade (P=0.0004). However, highly-expressed
CTCFL was not associated with the other examined clinical
characteristics (Table I).

Protein expression of CTCFL between HG-EOCs and
LG-EOCs. For further validation, the protein expression of
CTCFL in LG-EOCs EOCs and HG-EOCs was analyzed by
immunohistochemistry. As hypothesized, the protein expres-
sion of CTCFL in HG-EOCs samples was markedly higher
than LG-EOCs samples (Fig. 6A and B). Taken together, these
results suggested that CTCFL was associated with EOC grade
and may serve as a promising biomarker and therapeutic target
for HG-EOCs.

Discussion
As gene chip technology has advanced, genome-wide analysis
of microarrays have been increasingly applied to medical
research in order to identify differentially expressed genes in a variety of diseases including EOCs, as well as to explore the potential underlying molecular mechanisms of pathogenesis (11). An increasing number of microarray gene analysis investigating various diseases have been reported (11,23-25). For example, Singh et al (26) analyzed the genome-wide profile of the PIWI-interacting RNA-mRNA regulatory networks in EOCs. The study of Shi and Zhang (27) utilized microarray analysis to screen genes and regulatory factors involved in EOCs. Januchowski et al (28) used microarrays to identify novel genes associated with drug resistance in ovarian cancer cell lines. Wei et al (29) investigated the sequential gene changes in EOC induced by carboplatin via microarray analysis. However, few studies investigating biomarkers associated with EOC grade have been reported. Additionally, these studies have a limited sample size and different platforms resources, which lead to inconsistent results. Consequently, merging several eligible datasets together with normalization by using RMA analysis may produce more reliable results.

The present study was based on four public microarray datasets downloaded from the GEO database (GSE26193, GSE63885, GSE30161 and GSE9891), which collectively included 521 EOC samples. Initially, the differentially
expressed genes in each dataset were analyzed, and an intersection was obtained. CTCFL, EGFL6 and SAMHD1 were identified to be consistently upregulated among the GSE26193, GSE63885 and GSE30161 datasets. Following the addition of the GSE9891 dataset, only one overlapping candidate probe was identified to be upregulated among all the datasets. To compensate for the shortage of limited sample size and different platforms resources, the GSE26193, GSE63885 and GSE30161 datasets were merged for subsequent analysis and CTCFL was revealed to be the most upregulated gene in high-grade EOC. Based on gene enrichment analysis of dysregulated genes, the upregulated genes were most enriched in the ‘positive regulation of transcription from RNA polymerase II promoter’, while the downregulated genes were enriched in ‘signal transduction’ and ‘positive regulation of transcription from RNA polymerase II promoter’. These results indicated that the dysregulated genes in HG-EOCs may serve an underlying role in oncogene development and progression. Finally, RT-qPCR and immunohistochemical analysis demonstrated that the EOC grade was closely associated with the CTCFL level.

The aforementioned results demonstrated that CTCFL was the most upregulated gene in HG-EOCs. CTCFL belongs to the cancer testis antigen family (30), which is typically expressed in the testes (31). However, numerous studies investigating the high expression of CTCFL in multiple carcinomas have been reported, including breast cancer, lung cancer, endometrial carcinoma, prostate cancer and colon cancer, and the expression of CTCFL was associated with tumor size and histological differentiation (32-35). D’Arcy et al (32) reported that the CTCFL protein is closely associated with the occurrence and progression of breast cancer. Risinger et al (34) identified a similar expression profile of CTCFL in uterine cancer. The aforementioned studies suggested that CTCFL promoted tumorigenesis. Previous studies demonstrated that CTCFL was highly expressed in ovarian cancer, and the dysregulation was associated with DNA hypomethylation (36-38). At present, the pathophysiological role of CTCFL in tumor formation and progression is yet to be fully elucidated. To further investigate whether CTCFL was differentially expressed between HG-EOCs and LG-EOCs, the present study performed immunohistochemical analysis, and the results were consistent with the result of microarray datasets analysis. The results obtained in the current study suggested that CTCFL was the most upregulated gene in HG-EOCs compared with LG-EOCs. Taken together, the results of the present study indicated that CTCFL may act as an oncogene in the progression of EOC and may be a potential diagnostic biomarker and therapeutic target of EOC.

However, there are limitations to the present study. Due to the small sample size of EOC tissues in the experiment, further studies are required to verify the oncogenic role of CTCFL in EOC grade. Additionally, the mechanism of CTCFL which promotes malignant behaviors of ovarian cancer cells should be explored in depth. Finally, although the statistical analysis indicated a significant upregulation of CTCFL in HG-EOCs when compared with LG-EOCs, the RT-qPCR results demonstrated that the majority of patients had a value falling within the error bars for the LG-EOCs. Therefore, a larger sample size is required to define the CTCFL values that distinguish HG-EOCs from LG-EOCs.

In conclusion, CTCFL was the most upregulated gene in the selected datasets and may serve as a potential molecular biomarker to distinguish HG-EOCs from LG-EOCs. However, further investigations are required to explore the underlying mechanisms of CTCFL in HG-EOCs.

Acknowledgements
Not applicable.

Funding
This work was supported by the National Nature Science Foundation of China (grant. no. 81472442) and the Jiangsu Province Medical Innovation Team (grant. no. CXTDA2017008).

Availability of data and materials
The datasets analyzed during the current study are available in the GEO repository, https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE9891, https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE30161 and https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE63885. The datasets analyzed during the current study are available in the GEO repository, https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE26193.

Authors' contributions
WC designed the study. MG, CY and YJ analyzed and interpreted the microarray datasets, and produced the manuscript. MG wrote the paper and submitted the manuscript. HM and MF performed the experiments. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The present study was approved by the Research Ethics Committee of Nanjing Medical University. Written informed consent for the analysis of tissue specimens in this study was obtained from the patients.

Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
1. Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin 65: 5-29, 2015.
2. Bast RC Jr, Hennessy B and Mills GB: The biology of ovarian cancer: New opportunities for translation. Nat Rev Cancer 9: 415-428, 2009.
3. Prat J: Ovarian carcinomas: Five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch 464: 237-249, 2012.
4. Yan C, Jiang Y, Wan Y, Zhang L, Liu J, Zhou S and Cheng W: Long noncoding RNA NBAF-1 suppresses tumorigenesis and predicts favorable prognosis in ovarian cancer. Oncotargets Ther 10: 1993-2002, 2017.
5. Jacobs AS, Schwartz MD, Valdimarsdottir H, Nusbaum RH, Hooker GW, DeMarco TA, Heinzmann JE, McKinnon W, McCormick SR, Davis C, et al: Patient and genetic counselor perceptions of risk-penetrance versus teleogenetic counseling for hereditary breast ovarian cancer. Fam Cancer 15: 529-539, 2016.

6. Ganeshan D, Bhosale P, Wei W, Ramalingam P, Mudasiru-Dawodu E, Gershenson D, Sun C and Iyer R: Increase in post-tumour calcification on CT scan is not an indicator of response to therapy in low-grade serous ovarian cancer. Abdom Radiol (NY) 41: 1589-1595, 2016.

7. Hoppenot C, Eckert MA, Tienda SM and Lengyel E: Who are the long-term survivors of high grade serous ovarian cancer? Gynecol Oncol 148: 204-212, 2018.

8. Hacker KE, Uppal S and Johnston C: Principles of treatment for borderline, micropapillary serous, and low-grade ovarian cancer. J Natl Compr Canc Netw 14: 1175-1182, 2016.

9. Shih Ie M and Kurman RJ: Ovarian tumorigenesis: A proposed model based on morphological and molecular genetic analysis. Am J Surg Pathol 164: 1511-1518, 2004.

10. Khalique L, Ayhan A, Weale ME, Jacobs JJ, Ramus SJ and Gayther SA: Genetic intra-tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours. J Pathol 211: 286-295, 2007.

11. Chow YP, Alias H and Jamal R: Meta-analysis of gene expression in relapsed childhood B-acute lymphoblastic leukemia. BMC Cancer 17: 120, 2017.

12. Ding Y, Yang DZ, Zhai YN, Xue K, Xu F, Gu XY and Wang SM: Microarray expression profiling of long non-coding RNAs in epithelial ovarian cancer. Oncol Lett 14: 2523-2530, 2017.

13. Wang F, Fu Z, Dai C, Cao J, Liu X, Ju Y, Mu G, Yu Y, Zhang J, Hua X, et al: LncRNA expression profiling in normal ovary, benign ovarian cyst and malignant epithelial ovarian cancer. Sci Rep 6: 38983, 2016.

14. Mateescu B, Batista L, Cardon M, Gruosso T, de Feraudy Y, Lisowska KM, Olbryt M, Dudaladava V, Pamula-Pilat J, Nowicki M, Zabel M, et al: Micro-array-based detection and expression analysis of new genes associated with drug resistance in ovarian cancer cell lines. Oncotarget 8: 49944-49958, 2017.

15. Tophill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Tothill RW, and Mudasiru-Dawodu E: Detection of potentially crucial genes and regulatory factors involved in epithelial ovarian cancer using microarray analysis. Mol Med Rep 16: 3155-3160, 2017.

16. Yuan J, Huang L, Zhao Z, Liu Q, Wei L, Yu X, Li B and Qin Y: Hypomethylation of BORIS is a promising prognostic biomarker in hepatocellular carcinoma. Gene 629: 29-34, 2017.

17. Martin-Kleiner I: BORIS in human cancers-a review. Eur J Cancer 48: 929-935, 2012.

18. D'Arcy V, Pore N, Docquier F, Abdullaev ZK, Chernukhin I, Kita GX, Rai S, Smart M, Farrar D, Pack S, et al: BORIS, a parologue of the transcription factor, CTCF, is aberrantly expressed in breast tumours. Br J Cancer 98: 571-579, 2008.

19. Fang H, Yang DZ, Zhai YN, Xue K, Xu F, Gu XY and Wang SM: BORIS expression in ovarian cancer-faults and hints from DNA microarray study. Front Oncol 4: 6, 2014.

20. Ferriss JS, Kim Y, Duska L, Birrer M, Levine DA, Moskaluk C, Theodeorescu D and Lee JK: Multi-gene expression predictors of single drug responses to adjuvant chemotherapy in ovarian carcinoma: Predicting platinum resistance. PLoS One 7: e36050, 2012.

21. Torholl RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, et al: Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 14: 5198-5208, 2008.

22. Taminau J, Meganck S, Lazar C, Steenhoff D, Coletta A, Molter C, Duque R, de Schaatzen V, Weiss Solis DY, Bersini H, Goonesekere NC, Wang X, Ludwig L and Guda C: A meta-analysis of pancreatic microarray datasets yields new targets as cancer genes and biomarkers. PLoS One 9: e93046, 2014.

23. Chan SK, Griffith OL, Tai IT and Jones SJ: Meta-analysis of colorectal cancer gene expression profiling studies identifies consistently reported candidate biomarkers. Cancer Epidemiol Biomarkers Prev 17: 543-552, 2008.

24. Botting J, Edlund K, Lohr M, Hellwig B, Holmberg L, Lambe M, Berglund A, Ekman S, Bergqvist M, Ponten F, et al: Biomarker discovery in non-small cell lung cancer: Integrating gene expression profiling, meta-analysis, and tissue microarray validation. Clin Cancer Res 19: 194-204, 2013.

25. Goonesekere NC, Wang X, Ludwig L and Guda C: A meta-analysis of pancreatic microarray datasets yields new targets as cancer genes and biomarkers. PLoS One 9: e930485, 2018.

26. Shi C and Zhang Z: Screening of potentially crucial genes and regulatory factors involved in epithelial ovarian cancer using microarray analysis. Oncol Lett 14: 725-732, 2017.

27. Januchowski J, Sterzynska K, Zawierucha P, Rucinski M, Swierzewska M, Partyska M, Bednarek-Rajewska K, Brazert M, Nowicki M, et al: Micro-array-based detection and expression analysis of new genes associated with drug resistance in ovarian cancer cell lines. Oncotarget 8: 49944-49958, 2017.

28. D'Arcy V, Pore N, Docquier F, Abdullaev ZK, Chernukhin I, Kita GX, Rai S, Smart M, Farrar D, Pack S, et al: BORIS, a paralogue of the transcription factor, CTCF, is aberrantly expressed in breast tumours. Br J Cancer 98: 571-579, 2008.

29. Feng H, Yang DZ, Zhai YN, Xue K, Xu F, Gu XY and Wang SM: BORIS expression in ovarian cancer-faults and hints from DNA microarray study. Front Oncol 4: 6, 2014.

30. Ferriss JS, Kim Y, Duska L, Birrer M, Levine DA, Moskaluk C, Theodeorescu D and Lee JK: Multi-gene expression predictors of single drug responses to adjuvant chemotherapy in ovarian carcinoma: Predicting platinum resistance. PLoS One 7: e36050, 2012.

31. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, et al: Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 14: 5198-5208, 2008.

32. Taminau J, Meganck S, Lazar C, Steenhoff D, Coletta A, Molter C, Duque R, de Schaatzen V, Weiss Solis DY, Bersini H and Nowe A: Unlocking the potential of publicly available microarray data using inSilicoDb and inSilicoMerging R/Bioconductor packages. BMC Bioinformatics 13: 335, 2012.

33. Hong F, Breitling R, McEntee CW, Wittner BS, Nemhauser JL and Chory J: RankProd: A bioconductor package for detecting differentially expressed genes in meta-analysis. Bioinformatics 22: 2825-2827, 2006.

34. Huang da W, Sherman BT and Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57, 2009.

35. Ito K and Murphy D: Application of gelspot2 to Pharmacometric Graphics. CPT Pharmacometrics Syst Pharmacol 2: e79, 2013.

36. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta CT(T)) method. Methods 25: 402-408, 2001.